专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO03013536A9 METHODS FOR TREATMENT OF CANCER USING IRINOTECAN BASED ON UGT1A1 审中-公开
标题翻译：基于UGT1A1的IRINOTECAN治疗癌症的方法
公开(公告)号：WO03013536A9
公开(公告)日：2004-04-29
申请号：PCT/EP0208217
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH GUENTHER , KERB REINHOLD
发明人： HEINRICH GUENTHER , KERB REINHOLD
IPC分类号： C12N15/09 , A61K31/235 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/353 , A61K31/409 , A61K31/4152 , A61K31/4709 , A61K31/4741 , A61K31/4745 , A61K31/49 , A61K31/496 , A61K31/519 , A61K31/565 , A61K31/566 , A61K31/575 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P11/00 , A61P15/00 , A61P25/00 , A61P35/00 , A61P43/00 , C07D491/052 , C07D491/22 , C12Q1/68
CPC分类号： A61K31/4741 , A61K31/4745
摘要： The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a varient allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in a altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
摘要翻译：本发明涉及伊立替康或其衍生物在具有基因型的患者中制备用于治疗结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途，包含根据本发明的多核苷酸的变体等位基因。优选地，所述多核苷酸包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由变体等位基因编码的多肽的改变的活性与由相应的野生型等位基因。最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

2. 发明申请

WO03013535A9 USE OF IRINOTECAN FOR IMPROVED TREATMENT OF CANCER BASED ON MDR1 审中-公开
标题翻译：使用IRINOTECAN改善基于MDR1的癌症治疗
公开(公告)号：WO03013535A9
公开(公告)日：2004-04-29
申请号：PCT/EP0208220
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH GUENTHER , KERB REINHOLD
发明人： HEINRICH GUENTHER , KERB REINHOLD
IPC分类号： C12N15/09 , A61K31/235 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/353 , A61K31/409 , A61K31/4152 , A61K31/4709 , A61K31/4741 , A61K31/4745 , A61K31/49 , A61K31/496 , A61K31/519 , A61K31/565 , A61K31/566 , A61K31/575 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P11/00 , A61P15/00 , A61P25/00 , A61P35/00 , A61P43/00 , C07D491/052 , C07D491/22 , C12Q1/68
CPC分类号： A61K31/4741 , A61K31/4745
摘要： The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
摘要翻译：本发明涉及伊立替康或其衍生物在具有基因型的患者中制备用于治疗结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途，包含根据本发明的多核苷酸的变体等位基因。优选地，所述多核苷酸包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由变体等位基因编码的多肽的改变的活性与由相应的野生型等位基因。最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

3. 发明申请

WO03013534A9 METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5 审中-公开
标题翻译：基于CYP3A5的IRINOTECAN治疗癌症的方法
公开(公告)号：WO03013534A9
公开(公告)日：2004-04-29
申请号：PCT/EP0208219
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH GUENTHER , KERB REINHOLD
发明人： HEINRICH GUENTHER , KERB REINHOLD
IPC分类号： C12N15/09 , A61K31/235 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/353 , A61K31/409 , A61K31/4152 , A61K31/4709 , A61K31/4741 , A61K31/4745 , A61K31/49 , A61K31/496 , A61K31/519 , A61K31/565 , A61K31/566 , A61K31/575 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P11/00 , A61P15/00 , A61P25/00 , A61P35/00 , A61P43/00 , C07D491/052 , C07D491/22 , C12Q1/68
CPC分类号： A61K31/4741 , A61K31/4745
摘要： The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
摘要翻译：本发明涉及伊立替康或其衍生物在患者中制备用于治疗癌症，特别是结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途具有包含根据本发明的多核苷酸的变异等位基因的基因型。优选地，所述多核苷酸包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由与变体等位基因编码的多肽相比，由相应的野生型等位基因。最后，本发明涉及用于选择患有癌症，特别是结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

4. 发明申请

WO03013533A9 METHODS FOR IMPROVED TREATMENT OF CANCER WITH IRINOTECAN BASED ON MRP1 审中-公开
标题翻译：基于MRP1改善IRINOTECAN治疗癌症的方法
公开(公告)号：WO03013533A9
公开(公告)日：2004-04-29
申请号：PCT/EP0208200
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH GUENTHER , KERB REINHOLD
发明人： HEINRICH GUENTHER , KERB REINHOLD
IPC分类号： C12N15/09 , A61K31/235 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/353 , A61K31/409 , A61K31/4152 , A61K31/4709 , A61K31/4741 , A61K31/4745 , A61K31/49 , A61K31/496 , A61K31/519 , A61K31/565 , A61K31/566 , A61K31/575 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P11/00 , A61P15/00 , A61P25/00 , A61P35/00 , A61P43/00 , C07D491/052 , C07D491/22 , C12Q1/68
CPC分类号： A61K31/4741 , A61K31/4745
摘要： The present invention relates to the use of irinotecan or derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
摘要翻译：本发明涉及伊立替康或其衍生物在制备用于治疗癌症的药物组合物中的用途，特别是结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌患者中具有变体等位基因的基因型，其包含根据本发明的多核苷酸。优选地，所述多核苷酸包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由变体等位基因编码的多肽的改变的活性与由相应的野生型等位基因。最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

5. 发明申请

WO2003013533A2 MEANS AND METHODS FOR IMPROVED TREATMENT OF CANCER BASED ON MRP1 审中-公开
标题翻译：基于MRP1改善癌症治疗的手段和方法
公开(公告)号：WO2003013533A2
公开(公告)日：2003-02-20
申请号：PCT/EP2002/008200
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH, Günther , KERB, Reinhold
发明人： HEINRICH, Günther , KERB, Reinhold
IPC分类号： A61K31/4741
CPC分类号： A61K31/4741 , A61K31/4745
摘要： The present invention relates to the use of irinotecan or derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
摘要翻译：本发明涉及伊立替康或其衍生物在制备用于治疗癌症的药物组合物中的用途，特别是结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌患者中具有变体等位基因的基因型，其包含根据本发明的多核苷酸。优选地，所述多核苷酸包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由变体等位基因编码的多肽的改变的活性与由相应的野生型等位基因。最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

6. 发明申请

WO2003013537A3 IRINOTECAN FOR TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2003013537A3
公开(公告)日：2003-02-20
申请号：PCT/EP2002/008218
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH, Günther , KERB, Reinhold
发明人： HEINRICH, Günther , KERB, Reinhold
IPC分类号： A61K31/4745
摘要： The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a first, a second, a third, and/or a fourth variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a first, a second, a third and/or a fourth variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

7. 发明申请

WO03013536A2 MEANS AND METHODS FOR IMPROVED TREATMENT OF CANCER BASED ON UGT1A1 审中-公开
标题翻译：基于UGT1A1改善癌症治疗的手段和方法
公开(公告)号：WO03013536A2
公开(公告)日：2003-02-20
申请号：PCT/EP0208217
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH GUENTHER , KERB REINHOLD
发明人： HEINRICH GUENTHER , KERB REINHOLD
IPC分类号： C12N15/09 , A61K31/235 , A61K31/277 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/353 , A61K31/409 , A61K31/4152 , A61K31/4709 , A61K31/4741 , A61K31/4745 , A61K31/49 , A61K31/496 , A61K31/519 , A61K31/565 , A61K31/566 , A61K31/575 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P11/00 , A61P15/00 , A61P25/00 , A61P35/00 , A61P43/00 , C07D491/052 , C07D491/22 , C12Q1/68
CPC分类号： A61K31/4741 , A61K31/4745
摘要： The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a varient allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in a altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
摘要翻译：本发明涉及伊立替康或其衍生物在具有基因型的患者中制备用于治疗结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途，包含根据本发明的多核苷酸的变体等位基因。优选地，所述多核苷酸所包含的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，变体等位基因的表达改变，或由变体等位基因编码的多肽的改变的活性与由相应的野生型等位基因。最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

8. 发明申请

WO2003013534A3 METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5 审中-公开
公开(公告)号：WO2003013534A3
公开(公告)日：2003-02-20
申请号：PCT/EP2002/008219
申请日：2002-07-23
申请人： EPIDAUROS BIOTECHNOLOGIE AG , HEINRICH, Günther , KERB, Reinhold
发明人： HEINRICH, Günther , KERB, Reinhold
IPC分类号： A61K31/4745
摘要： The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

9. 发明申请

WO2004018512A3 POLYMORPHISMS IN THE HUMAN GENES FOR OCT1 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 审中-公开
标题翻译： OCT1基因多态性及其在诊断和治疗应用中的应用
公开(公告)号：WO2004018512A3
公开(公告)日：2004-07-01
申请号：PCT/EP0309356
申请日：2003-08-22
申请人： EPIDAUROS BIOTECHNOLOGIE AG , KERB REINHOLD , KOEPSELL HERMANN , BRINKMANN ULRICH
发明人： KERB REINHOLD , KOEPSELL HERMANN , BRINKMANN ULRICH
IPC分类号： A01K67/027 , A61K38/00 , A61K38/17 , A61K48/00 , C07K14/47 , C07K16/18 , C12N15/12 , C12Q1/68 , G01N33/50 , G01N33/53
CPC分类号： C07K14/4702 , A01K2217/05 , A61K38/00 , C12Q1/6883
摘要： The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.
摘要翻译：本发明涉及多态性OCT1多核苷酸。此外，本发明涉及包含本发明的多核苷酸的基因或载体以及用本发明的多核苷酸或基因进行基因工程改造的宿主细胞。此外，本发明涉及产生分子变体多肽或其片段的方法，产生能表达分子变异多肽的细胞的方法，以及由本发明的多核苷酸或基因编码的多肽或其片段，方法或由本发明的方法产生的细胞。此外，本发明涉及特异性结合本发明多肽的抗体。此外，本发明涉及转基因非人类动物。本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。另外，本发明涉及生产药物组合物的方法和诊断疾病的方法。此外，本发明涉及检测本发明多核苷酸的方法。此外，本发明包含诊断和药物组合物。甚至更多地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。最后，本发明涉及一种诊断试剂盒。

10. 发明申请

WO2004018512A2 POLYMORPHISMS IN THE HUMAN GENES FOR OCT1 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 审中-公开
标题翻译： OCT1人类基因多态性及其在诊断和治疗应用中的应用
公开(公告)号：WO2004018512A2
公开(公告)日：2004-03-04
申请号：PCT/EP2003/009356
申请日：2003-08-22
申请人： EPIDAUROS BIOTECHNOLOGIE AG , KERB, Reinhold , KOEPSELL, Hermann , BRINKMANN, Ulrich
发明人： KERB, Reinhold , KOEPSELL, Hermann , BRINKMANN, Ulrich
IPC分类号： C07K14/47
CPC分类号： C07K14/4702 , A01K2217/05 , A61K38/00 , C12Q1/6883
摘要： The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.
摘要翻译：本发明涉及多晶型OCT1多核苷酸。此外，本发明涉及包含本发明的多核苷酸的基因或载体，并涉及用本发明的多核苷酸或基因进行遗传工程改造的宿主细胞。此外，本发明涉及用于产生分子变体多肽或其片段的方法，用于产生能够表达分子变体多肽的细胞的方法，以及由本发明的多核苷酸或基因编码的多肽或其片段，或可由方法或由本发明方法生产的细胞。此外，本发明涉及特异性结合本发明多肽的抗体。此外，本发明涉及转基因非人动物。本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。此外，本发明涉及制备药物组合物的方法和诊断疾病的方法。此外，本发明涉及本发明的多核苷酸的检测方法。此外，本发明包括诊断和药物组合物。更进一步地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。最后，本发明涉及诊断试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式